


Measurable Residual Disease (MRD)

Get the complete MRD story with targeted NGS profiling

Complete response **may not provide** a complete picture

Detection of residual disease is a powerful prognostic factor, an important instrument for therapeutic decision-making, and is the best way to monitor therapeutic response and predict relapse.¹



Expediting development of **new treatment strategies** with MRD




Current U.S. Clinical Trials using MRD³

Patients labeled as **MRD-negative** by **standard tests still face relapse rates of**


25% or higher⁴

Next-generation sequencing (NGS) MRD assays provide a comprehensive analysis of AML-specific genes **in a single assay**¹




Morphology

Only a limited number of cells evaluated. Likely to detect only high levels of residual disease.



Flow Cytometry and PCR

Limited in the number of cancer cell markers evaluated. Subclonal populations may be missed.



Next-Generation Sequencing

Can detect and quantify mutations across multiple AML-specific genes simultaneously, revealing emerging clonal populations and simplifying monitoring.

● Healthy cell ● Original disease clone ● Emerging sub-clone

Stay one step ahead of AML with **NGS-based MRD longitudinal monitoring**^{1,5}

- Detect extremely low levels of disease
- Identify emerging clones
- Personalize treatment strategies
- Monitor for relapse

Discover MRD solutions with enhanced sensitivity.

[Learn more](#)

References:

¹ Li, W. *Leukemia*. Exon Publications. 2022; 79-100.
² Aitken, M.J.L., Ravandi, F., Patel, K.P., Short, N.J., *J Hematol Oncol*. 2021; 14, 137.
³ ClinicalTrials.gov [Accessed 4/5/2024]
⁴ Short, N.J., Zhou, S., Fu, C. et al. *JAMA*. 2020; 6(12): 1890-1899.
⁵ Heuser, M., Freeman, S.D., Ossenkoppele, G.J. et al. *Blood*. 2021;138(26): 2753-2767.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in Europe and Turkey. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in Europe, Turkey and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at support@sophigenetics.com to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS' use of third-party trademarks does not indicate any relationship, sponsorship, or goods and/or services and shall be considered nominative fair use under the trademark law.

Somatic gene variant annotations and related content have been powered by, without limitation, The Jackson Laboratory Clinical Knowledgebase (JAX-CKB™).